Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Overview of attention for article published in The Lancet Diabetes & Endocrinology, June 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

news: 3 news outlets
twitter: 100 X users

f1000: 1 research highlight platform
bluesky: 1 Bluesky user

Readers on

mendeley: 173 Mendeley

So far, Altmetric has seen 114 X posts from 100 X users, with an upper bound of 625,893 followers.

Imatinib for T1D trial. Not an ideal solution.

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Diabetes & Endocrinology https://t.co/Dp2f2UZgpv

RT @thesugarscience: #Imatinib therapy for patients with recent-onset #T1D from June 2021. @DoctorDiMeglio @kickassscience1 https://t.co/c…

#Imatinib therapy for patients with recent-onset #T1D from June 2021. @DoctorDiMeglio @kickassscience1 https://t.co/cIrGvTZStl

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 110 additional X posts.